Bacillus Calmette-Guérin enhancement of colony-stimulating activity and myeloid colony formation following administration of cyclophosphamide.
Pretreatment of mice with Bacillus Calmette-Guérin (BCG) enhances recovery of the peripheral granulocyte count from cyclophosphamide (CTX)-induced leukopenia. In the present study, in vitro bone marrow culture was used to assess the effect of BCG pretreatment on serum levels of myeloid colony-stimulating activity and on regeneration of bone marrow myeloid colony-forming units (CFU-c) following CTX. C57BL/6 mice received either BCG or 0.9% NaCl solution i.p. 8 days prior to the administration of CTX (300 mg/kg i.p.). Following CTX, peak serum levels of myeloid colony-stimulating activity were strikingly higher in the BCG-pretreated mice [1320 +/- 30 (S.E.) units] than in the 0.9% NaCl solution-pretreated mice (764 +/- 37 units). BCG pretreatment also resulted in higher numbers of marrow CFU-c during recovery from CTX (e.g., 43.9 +/- 1.8 versus 20.0 +/- 0.9 myeloid colonies/10(5) marrow cells, Day 3 post-CTX). However, neither the rate of decline nor the absolute nadir of CFU-c, nor CFU-c cell cycle characteristics were affected by the pretreatment. The initial effect of i.p. BCG pretreatment on recovery from CTX-induced granulocytopenia is an augmentation of serum myeloid colony-stimulating activity which precedes the enhanced regeneration of CFU-c and the accelerated recovery of the peripheral granulocyte count.
D000818:Animals; D001500:BCG Vaccine; D001853:Bone Marrow / Q000187:drug effects; D002453:Cell Cycle; D003114:Colony-Forming Units Assay; D003520:Cyclophosphamide / Q000494:pharmacology*; D006098:Granulocytes / Q000187:drug effects; D007970:Leukopenia / Q000139:chemically induced*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL
D001500:BCG Vaccine; D003520:Cyclophosphamide